This site is for informational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult your healthcare provider.
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis | MicrobiomeTrials
← Back to trials NCT05652335
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis Recruiting PHASE1 INTERVENTIONAL
Read the full scientific description See full eligibility requirements Trial Details Start: 2022-11-22Est. Completion: 2027-04-19
Enrollment target: 180 participantsLocations City of Hope, Duarte, California, United States City of Hope Orange County Lennar Foundation Cancer Center, Irvine, California, United States University of California San Francisco, San Francisco, California, United States Colorado Blood Cancer Institute, Denver, Colorado, United States Icahn School of Medicine at Mt. Sinai, New York, New York, United States Memorial Sloan Kettering Cancer Center, New York, New York, United States Levine Cancer Institute, Charlotte, North Carolina, United States University of Pennsylvania Division of Hematology Oncology Perelman Center for Advanced Medicine, Philadelphia, Pennsylvania, United States MD Anderson Cancer Center, Houston, Texas, United States UZ Antwerpen, Edegem, Belgium UZ Gent, Ghent, Belgium CHU de Liege, Liège, Belgium CHU Nantes, Nantes, France CHU Lyon Sud, Pierre-Bénite, France Chu Rennes Hopital Pontchaillou, Rennes, France Institut Claudius Regaud, Toulouse, France Japanese Red Cross Medical Center, Shibuya City, Japan Other microbiome trials you might be interested in Multiple Myeloma
The purpose of this study is to learn about the study medicine called elranatamab.This study aims to compare elranatamab…
Mobile, United States Est. completion Aug 30, 2026
Multiple Myeloma
The primary purpose is to determine the safety and tolerability of belantamab mafodotin in combination with nirogacestat…
Boston, United States Est. completion Apr 17, 2025
Osaka University Hospital, Suita-shi, Japan
The Cancer Institute Hospital of JFCR, Tokyo, Japan
VUMC Amsterdam, Amsterdam, Netherlands
Universitair Medisch Centrum Groningen, Groningen, Netherlands
UMC Utrecht, Utrecht, Netherlands
Hosp. Univ. Germans Trias I Pujol, Badalona, Spain
Hosp Clinic de Barcelona, Barcelona, Spain
Hosp Univ Fund Jimenez Diaz, Madrid, Spain
Clinica Univ. de Navarra, Pamplona, Spain
Hosp Clinico Univ de Salamanca, Salamanca, Spain
University College Hospital, London, United Kingdom
Royal Marsden Hospital, Sutton, United Kingdom Phase 1
SUSPENDED
Multiple Myeloma Relapsed and/or Refractory Multiple Myeloma (RRMM)
Background:
Multiple myeloma (MM) is a type of blood cancer that affects a person s immunity. MM returns after treatmen…
Bethesda, United States Completed Jan 1, 2033